P01A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti–platelet-derived growth factor α (pdgfrα) monoclonal antibody, in advanced soft tissue sarcoma (sts)